Navigation Links
Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
Date:5/18/2009

OSAKA, Japan, and IRVINE, Calif., May 18 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) and IDM Pharma, Inc. (Nasdaq: IDMI) today announced that Takeda America Holdings, Inc., a wholly-owned subsidiary of Takeda (Takeda America), and IDM Pharma have entered into an agreement for Takeda America to acquire IDM Pharma. Takeda America has established Jade Subsidiary Corporation as a wholly-owned subsidiary to effect that transaction. Under the agreement, Takeda America will purchase all of IDM Pharma's outstanding shares for US$2.64 per share in an all cash tender offer followed by a merger.

Millennium: The Takeda Oncology Company, Takeda's business unit responsible for global oncology strategy and development, will have global development responsibility for MEPACT(R), IDM Pharma's primary asset, and Takeda Pharmaceuticals Europe Ltd. will be responsible for commercializing MEPACT in Europe.

IDM Pharma received European marketing approval for MEPACT (mifamurtide), a therapy indicated for the treatment of non-metastatic osteosarcoma (malignant bone cancer) following surgical removal of the tumor (resection) in children, adolescents and young adults. Osteosarcoma is a rare and often fatal disease, with approximately 1,200 new cases diagnosed in Europe each year. The disease affects primarily children and young adults. The European Commission formally granted a centralized marketing authorization for MEPACT on March 6, 2009, allowing it to be marketed in the 27 EU member states, as well as in Iceland, Liechtenstein and Norway.

"MEPACT delivers a demonstrated survival advantage for young patients with a specific type of bone cancer and provides Takeda with an approved therapy that contributes immediately to our top-line growth," said Erich Brunn, CEO of Taked
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited; IDM Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Takeda to Create Global Centers of Excellence
2. Takeda Receives New Information on Alogliptin (SYR-322) NDA
3. Healthcare Businesswomens Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company
4. Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured
5. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
6. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
7. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
8. Takeda Completes Acquisition of Millennium
9. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
10. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
11. Takeda Announces New U.S. Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2014)... Seattle, Wa (PRWEB) August 02, 2014 According ... Vkool.com, this is a comprehensive dating guide for women. The ... attract the man they want easily. The book also teaches ... commitment issues. , Vkool reveals in its review that ...     Chapter 1 – What’s Your Relationship Story? , ...
(Date:8/2/2014)... Lakewood Park Apartment Homes , located ... side, has undertaken a project that promises to help ... sense, while improving the “green” appearance of its already ... announced that Lakewood Park is currently preparing garden plots ... about being able to offer this opportunity to our ...
(Date:8/2/2014)... 02, 2014 When the Black Hat conventioneers ... this year, one thing can be always counted on, plenty ... as fear, uncertainty and doubt. The run-up has already ... article published by Reuters on July 31st about how ... or keyboard to successfully infect a system with malware, completely ...
(Date:8/1/2014)... 2014 Cannabis use among young people has ... to 17 having used marijuana at least once and 17 ... “Say ‘No’ to Drugs, Say ‘Yes to Life,’ volunteers from ... youth this summer with factual information about drugs, to help ... Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ to Life,” volunteers ...
(Date:8/1/2014)... brain plays a central role in regulating appetite and ... in the brain,s control of food intake and body ... process has been unclear. A new study ... that PPARγ activity in a type of neuron known ... response to high-fat diet. Sabrina Diano and colleagues ...
Breaking Medicine News(10 mins):Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 2Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 3Health News:Lexington’s Lakewood Park Apartments Getting Into Gardening 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 3Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 4Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 5Health News:Addressing a Serious Issue Affecting German Teens 2
... committee Sunday said medicines sold in shops would indicate ... 2. ,The decision was taken in a meeting ... of chemicals, fertilizers and steel. The members were discussing ... members decided that the 354 drugs in the national ...
... is where the Codex Alimentarius Commission’s role is crucial. If ... uphill task to maintain standards in taste and safety. ... to the European community. This is indeed a combined worthy ... Agriculture Organization of the United Nations. ,They are ...
... The government has planned to alter citeria for jobless benefit ... illness under //reforms being unveiled this week. ,Work and ... off benefit and into work following the publishing of his ... the personal capability assessment which is used to decide whether ...
... Recently an UCLA study by a team of researchers ... carotid atheromas formation in patients //at a higher risk ... link may be due to blockages containing calcium in ... carotid artery. ,These blockages, or atheromas, contain ...
... the disease strides ahead with greater determination from obscurity to ... why is the pandemic// outpacing us, or are countries acting ... million people and affected another 40 million worldwide? ... York for the review meeting to the United Nations General ...
... consider Medical Council of India seniority on appointment in ... ,Talking to reporters here Association General Secretary, ... about 34,000 doctors are unemployed in India in which ... is recruiting doctors for government health services, the government ...
Cached Medicine News:Health News:AIDS: Why the pandemic outpaces us 2Health News:AIDS: Why the pandemic outpaces us 3
(Date:8/1/2014)... Aug. 1, 2014 Dyadic International, Inc. ("Dyadic") ... proprietary technologies are used to develop, manufacture and sell ... biopharmaceutical and industrial enzyme industries, announced today that it ... ended June 30, 2014 after market close on Thursday, ... that day at 5:00 p.m. Eastern Time to discuss ...
(Date:7/31/2014)... 1, 2014 Cipla ... heute bekannt, vor kurzem für OneDose ReadyfusOR™ ... nach chirurgischen Eingriffen eine kommerzielle Zusammenarbeit begonnen ... Union und weiterer europäischer Länder abdeckt. Cipla ... Ropivacain gefüllte OneDose ReadyfusOR später in diesem ...
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ) a ... delivery systems for the eye today reported revenue for ... million, a 10% increase over $18.2 million reported for ... basis, revenues grew 11% during the second quarter of ... effect of foreign currency exchange reduced sales by $0.1 ...
Breaking Medicine Technology:Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... FARMINGDALE, N.Y., Nov. 2, 2011 Misonix, Inc. ... company that designs, manufactures, and markets innovative therapeutic ... cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical ... Ultrasonic Bone Cutting System and the SonaStar® Ultrasonic ...
... 2011 Perrigo Company (Nasdaq: PRGO ; TASE) ... Drug Administration (FDA) a New Drug Application (NDA) for testosterone ... the owner of the Reference Listed Drug of its filing. ... the United States District Court for the District of New ...
Cached Medicine Technology:Misonix Announces its Exhibition at the European Association of Neurosurgical Societies 2Misonix Announces its Exhibition at the European Association of Neurosurgical Societies 3Perrigo Confirms Filing for Testosterone Gel 1.0% and Announcement of Patent Infringement Lawsuit by Abbott 2
... has been designed for use with Bioneer's ... can handle 96 samples (Plasmid DNA, Genomic ... and purification. While conventional kits use centrifugal ... BioVac 96 Vacuum Manifold uses vacuum pressure ...
Plastic Tray Type Vacuum Manifold...
... manifold is designed to efficiently process ... holds one deep well plate and ... are drawn through the wells ... microplates. The base holds and ...
QIAvac 96 is designed for efficient processing of QIAGEN 96-well plates....
Medicine Products: